The phosphodiesterase-4 inhibitor, FCPR16, attenuates ischemia-reperfusion injury in rats subjected to middle cerebral artery occlusion and reperfusion
Sign Up to like & getrecommendations! Published in 2018 at "Brain Research Bulletin"
DOI: 10.1016/j.brainresbull.2017.11.010
Abstract: Current phosphodiesterase-4 (PDE4) inhibitors exert beneficial effects in central nervous system diseases via anti-inflammatory and anti-apoptotic properties, but many of them are plagued by side effects like nausea and emesis. FCPR16, a novel PDE4 inhibitor… read more here.
Keywords: cerebral artery; subjected middle; middle cerebral; fcpr16 ... See more keywords
Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP+-induced decline of mitochondrial membrane potential and oxidative stress
Sign Up to like & getrecommendations! Published in 2018 at "Redox Biology"
DOI: 10.1016/j.redox.2018.02.008
Abstract: Phosphodiesterase 4 (PDE4) is a promising target for the treatment of Parkinson's disease (PD). However, the underlying mechanism has not yet been well elucidated. Additionally, most of current PDE4 inhibitors produce severe nausea and vomiting… read more here.
Keywords: mpp induced; fcpr16; mitochondrial membrane; membrane potential ... See more keywords